Summit Therapeutics PLC (SMMT) — Cash Flow Reinvestment Rate

Latest as of December 2022: 152.67x

Summit Therapeutics PLC (SMMT) has a Cash Flow Reinvestment Rate of 152.67x as of December 2022, reinvesting $646.06 Million (capex $994.38K plus investments $-645.06 Million) from operating cash flow of $4.23 Million. Explore SMMT capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

152.67x
(Capex + Investments) / Operating CF

Total Reinvested

$646.06 Million
Capex + Investments

Operating Cash Flow

$4.23 Million
USD

Capital Expenditures

$994.38K
USD

Summit Therapeutics PLC Cash Flow Reinvestment Rate (2004–2016)

Historical reinvestment intensity for Summit Therapeutics PLC across 2 annual periods. Also explore how large is Summit Therapeutics PLC's balance sheet for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Summit Therapeutics PLC (2004–2016)

Year-by-year capital reinvestment analysis for Summit Therapeutics PLC. For live market cap and broader valuation context, see market cap of Summit Therapeutics PLC.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2016 0.01x $209.99K $15.18 Million $110.00K ▼ -94.1%
2004 0.23x $13.18K $56.48K $13.18K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow